Alkermes plc Launches Pathways Awards to Support Neuroscience Research for Mental Health Innovation

Alkermes Champions Neuroscience Research with Pathways Awards Initiative

Alkermes plc (Nasdaq: ALKS) is set to launch its eighth annual Alkermes Pathways Research Awards® program, a significant initiative aimed at supporting early-career researchers in the field of neuroscience. Scheduled to accept applications from September 15 to December 15, 2025, the program focuses on enhancing understanding of critical areas such as schizophrenia, bipolar I disorder, and the recently included research on sleep and circadian disturbances associated with these mental health conditions. This year, the program will award grants of up to $100,000 per project, specifically targeting researchers who have recently entered the academic field, thereby fostering innovation and discovery in the understanding of complex neurological disorders.

Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Alkermes, underscores the company’s commitment to nurturing new talent in research. By emphasizing the importance of early-career investigators, Alkermes aims to drive significant advancements in neuroscience and mental health. The decision to broaden the scope of research to incorporate sleep and circadian rhythm disturbances recognizes their emerging relevance in the treatment of psychiatric disorders, mirroring a growing consensus in the scientific community about the interconnectedness of these factors. This initiative not only aims to provide financial backing but also acts as a catalyst for innovative research that can ultimately enhance treatment options for individuals suffering from these debilitating conditions.

The Pathways Research Awards program positions Alkermes as a leader in the neuroscience domain, reinforcing its dedication to advancing knowledge and improving patient outcomes. By investing in the next generation of researchers, the company facilitates a platform for groundbreaking studies that may lead to more effective therapies. As the landscape of mental health research evolves, Alkermes remains focused on contributing meaningfully to the scientific community, ensuring that new insights and treatments emerge to address the challenges faced by those with mental illness.

In addition to the Pathways Research Awards, Alkermes continues to explore collaborative opportunities to strengthen its role in mental health advancements. By engaging with various stakeholders in the field, the company seeks to amplify the impact of research initiatives and promote innovative solutions. This approach aligns with Alkermes’ mission to transform the treatment landscape for individuals affected by complex neurological disorders, ensuring that they receive the care and support they need.